Here, in cDC1-deficient hosts, CD40 agonist primed tumor-specific T cells that coexpressed Klrg1 and Lag3, or a Treg marker Foxp3, and these T cells appeared dispensable for tumor control. This evidence concerns the gene LAG3 and neoplasm.